In lung cancer patients, previous studies reported that high expression of IDO1 was associated with poor prognosis and survival in non-small-cell lung cancer [21, 34], and IDO1 activity was linked to primary resistance to immunotherapy in non-small-cell lung cancer [25]. Here, IDO1 is linked to lung carcinoma.